Metrics. Though the characteristics of carboplatin-related hypersensitivity reactions are widely reported, limited data are available regarding such reactions in different types of patients. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. All funding for this site is provided directly by ESMO. These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. For more detailed information on the cookies we use, please check our Privacy Policy. J. Clin. In addition, the development of a new generation of platinum cytotoxic drugs to avoid hypersensitivity reactions is warranted. The .gov means its official. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Pediatric. (2005). Cancer statistics, 2016. A. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. Borrs Cuartero J, Farzanegan Miano R, Torres Gorriz MC, Germn Snchez A, Aznar RC, Raducan I, Castell Carrascosa JV, Sanchez Hernandez A, Enrique E. Front Allergy. Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. Res. National Library of Medicine (2006). Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. 31, 45254528. (2003) reported that paclitaxel with platinum improves overall survival compared to conventional platinum-based chemotherapy among patients with relapsed platinum-sensitive ovarian cancer. European Hematology Association (EHA) and European . doi: 10.1016/j.ygyno.2007.06.016, Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., et al. Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan No use, distribution or reproduction is permitted which does not comply with these terms. In 74 of the 75 patients, the hypersensitivity reactions subsided within several minutes to several hours after onset, and the patients recovered without any sequelae. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Zhi. (2016). This site uses cookies. Annals of Oncology (2021) 32 (suppl_5): S407-S446. (2001). ESMO Virtual Congress 2020 | OncologyPRO doi: 10.7759/cureus.24515. Abe, A., Ikawa, H., and Ikawa, S. (2010). doi: 10.1093/annonc/mdx216. All women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with carboplatin alone or a carboplatin-based combination chemotherapy regimen at a single hospital between January 2006 and December 2013 were retrospectively recruited. This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. Study conception and design: Y-HT and W-FC. Before Int. For salvage chemotherapy in the case of recurrent disease, we administered chemotherapeutic regimens including carboplatin with paclitaxel, gemcitabine, or liposomal doxorubicin. This site needs JavaScript to work properly. Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to carboplatin [from Sloane et al. This site uses cookies. Ann. Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. Oncol. Federal government websites often end in .gov or .mil. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Oncol Res Treat. 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. Furthermore, Moon et al. Epub 2019 Jul 3. For more detailed information on the cookies we use, please check our Privacy Policy. Risk Factors of Hypersensitivity to Carboplatin in Patients with Epub 2012 May 3. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. The symptoms and signs of the 75 women with carboplatin-related hypersensitivity reactions are given in Table 4. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. ESMO is a Swiss-registered not-for-profit organisation. This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). Hypersensitivity reactions are generally unexpected, regulated by the immune system, and allergic in nature. Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4). Have a look to the ESMO 2017 Programme online! Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Gynecol. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. Severe reactions are less frequent and may be fatal without appropriate intervention. The incidence of carboplatin-related hypersensitivity correlated with cycle number and dose, with the first episode occurring at a median of 12 cycles and 6,816 mg. Bookshelf Oncol. FOIA (2016). Background Hypersensitivity reactions (HSRs) are sometimes associated with the administration of certain cancer drugs. Patients who previously received platinum compounds were excluded. Management of infusion reactions to systemic anticancer therapy: ESMO doi: 10.1200/JCO.2003.02.153, Parmar, M. K., Ledermann, J. Int. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. EHA Endorsement of ESMO Clinical Practice Guidelines for Dia - LWW Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment.
12380 River Ridge Dr, Folsom, La, Articles E